Treatment with alirocumab in drug-naïve patients with hypercholesterolemia and carotid atherosclerosis decreased fibrinogen, FVII and plasminogen activator inhibitor-1 (PAI-1) antigen levels, and it thereby increased fibrinolytic activation [67]. The gene discussed is SERPINE1; the disease is carotid atherosclerosis.